Ingalls & Snyder LLC’s Marker Therapeutics MRKR Stock Holding History

Ingalls & Snyder LLC’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,540	Closed	-$43K	–	466
2021 Q2	$43K	Hold	1,540	–	–	﹤0.01%	455
2021 Q1	$34K	Hold	1,540	–	–	﹤0.01%	433
2020 Q4	$22K	Sell	1,540 -770	-33%	-$12K	﹤0.01%	423
2020 Q3	$35K	Hold	2,310	–	–	﹤0.01%	363
2020 Q2	$48K	Hold	2,310	–	–	﹤0.01%	394
2020 Q1	$44K	Sell	2,310 -160	-6%	-$4.08K	﹤0.01%	401
2019 Q4	$71K	Sell	2,470 -5,690	-70%	-$207K	﹤0.01%	390
2019 Q3	$417K	Sell	8,160 -640	-7%	-$37.8K	0.02%	312
2019 Q2	$697K	Sell	8,800 -80	-0.9%	-$4.75K	0.03%	257
2019 Q1	$586K	Hold	8,880	–	–	0.03%	268
2018 Q4	$493K	Buy	8,880 +5,230	+143%	+$381K	0.03%	279
2018 Q3	$330K	Buy	+3,650	New	+$313K	0.01%	345

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ingalls & Snyder LLC's MRKR Position: Q3 2021 in Review

Ingalls & Snyder LLC sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 1,540 shares — an estimated $43K sold.

Ingalls & Snyder LLC first reported a position in MRKR in Q3 2018 and held it in 12 quarters. The position peaked at $697K in Q2 2019. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

Ingalls & Snyder LLC reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
Ingalls & Snyder LLC sold 1,540 Marker Therapeutics shares in Q3 2021, an estimated $43K.
Ingalls & Snyder LLC first reported a position in Marker Therapeutics in Q3 2018 and held it in 12 quarters.
Ingalls & Snyder LLC's Marker Therapeutics position peaked at $697K in Q2 2019.
63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2021, filed 27 Oct 2021.